Acute cardiac care & resuscitation
Short-Term Outcomes of Heart Transplant Patients Bridged with Impella 5.5 Ventricular Assist Device
Authors' conclusion
Impella 5.5 temporary left ventricular assist device optimizes care of heart transplant recipients providing superior haemodynamic support, mobility, improved renal function, pulmonary haemodynamics, and right ventricular function. Utilizing Impella 5.5 as a direct bridging strategy to heart transplantation resulted in excellent outcomes.
Study context
- Population
- Advanced HF patients bridged with Impella 5.5 to heart transplantation, March 2020–March 2021
- Participants
- 16 patients
- Outcome
- Outcomes during Impella support and after transplantation
Main finding
As reported in the abstract
| Group | Value | Lactate dehydrogenase, median (range) |
|---|---|---|
| Impella 5.5 | median 19 (range 3–31) days | 220 (149-430) |
Impella 5.5
Valuemedian 19 (range 3–31) days
Lactate dehydrogenase, median (range)220 (149-430)
- Median serum creatinine during Impella support decreased from 1.55 mg/dL to 1.25
- P = 0.007
- Pulmonary artery pulsatility index increased from 2.56 (0.86-10) to 4.2 (1.3-10)
- P = 0.048
- RV function improved
- P = 0.003
Observational data: associations, not effects.
Original publication
Short-Term Outcomes of Heart Transplant Patients Bridged with Impella 5.5 Ventricular Assist Device. ESC Heart Fail. Published 3 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →